Pressroom: Press Releases

2012

Childhood Cancer Treatment Found to Pose Similar Risk for Breast Cancer as BRCA Mutations

New data reveals that women treated with radiation to the chest for childhood cancer have a high risk of developing breast cancer similar to that of women with BRCA1/2 mutations. The study, led by Memorial Sloan Kettering Cancer Center biostatistician Chaya Moskowitz, PhD, was presented today at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.

June 4, 2012
Testing for Mutations Identified in Squamous Cell Lung Cancer Tumors Helps Personalize Treatment

Researchers from Memorial Sloan Kettering Cancer Center have begun testing for three new genetic targets and found that together they occur in approximately 50 percent of patients with squamous cell carcinomas of the lung, which affects 40,000 Americans each year. Initial findings of the research will be presented on June 4 at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.

May 16, 2012
Memorial Sloan Kettering Commack Offers Free Mammograms to Eligible Women on Long Island

Women on Long Island who don’t have insurance or who are underinsured may be able to take advantage of free mammograms at Memorial Sloan Kettering Cancer Center Commack.

May 8, 2012
Memorial Sloan Kettering's Website Nominated for Webby Award

Memorial Sloan Kettering Cancer Center’s website has been nominated for The Webby Award, the most prestigious international award honoring excellence on the Internet. Selected from among nearly 10,000 total entries, the Center’s website is one of five nominated in the Health category.

April 12, 2012
Antibody Therapy Prevents Gastrointestinal Damage following Radiation Exposure in Mice

A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident.

April 4, 2012
Memorial Sloan Kettering Cancer Center, IBM to Collaborate in Applying Watson Technology to Help Oncologists

Memorial Sloan Kettering and IBM have agreed to collaborate on the development of a powerful tool built upon IBM Watson to provide medical professionals with improved access to comprehensive cancer data and practices.

March 22, 2012
Genetic Profiling Can Help Doctors More Accurately Predict Prognosis and Guide Treatment Decisions for Leukemia Patients

Researchers have identified a set of genetic abnormalities in patients with acute myelogenous leukemia (AML) that doctors can use to more accurately predict patients’ prognoses and select treatments that are most likely to benefit them. The study, led by investigators at Memorial Sloan Kettering Cancer Center, will be published in the March 22 issue of the New England Journal of Medicine.

March 14, 2012
Rare Medical Phenomenon Of Systemic Tumor Disappearance Following Local Radiation Treatment Reported In A Patient With Metastatic Melanoma

A rarely seen phenomenon in cancer patients — in which focused radiation to the site of one tumor is associated with the disappearance of metastatic tumors all over the body — has been reported in a patient with melanoma treated with the immunotherapeutic agent ipilimumab (Yervoy™).

March 7, 2012
Colonoscopy Prevents Deaths From Colon Cancer

For the first time, a new study has shown that removing polyps by colonoscopy not only prevents colorectal cancer from developing, but also prevents deaths from the disease. Patients in the study were evaluated for up to 23 years after having the procedure, providing the longest follow-up results to date.

February 22, 2012
Cycle for Survival Event Advances Research and Treatments for Rare Cancers

More than 10,000 people nationwide will participate in Memorial Sloan Kettering Cancer Center’s sixth annual Cycle for Survival event taking place this February at Equinox clubs in New York City, Long Island, Washington D.C., Chicago, San Francisco, and Los Angeles.

February 1, 2012
Targeted Therapy Improves Overall Survival in Men with Late-Stage Prostate Cancer

The investigational oral drug MDV3100 significantly improved overall survival in patients with advanced prostate cancer, results of a large, phase III study show.

January 31, 2012

2011

Memorial Sloan Kettering Receives $50 Million in Honor of Josie Robertson

As a tribute to Memorial Sloan Kettering Board member Josephine “Josie” Robertson, Memorial Sloan Kettering has joined with The Robertson Foundation to undertake two high-profile initiatives — the Josie Robertson Surgery Center and the Josie Robertson Investigators Program — made possible by a $50 million commitment from The Robertson Foundation.

December 21, 2011
Experimental Treatment Could Improve Stem Cell Transplants

A Memorial Sloan Kettering Cancer Center study suggests that a new, experimental treatment could make bone marrow and stem cell transplantation more effective and safe.

December 10, 2011
Researchers Discover Why New Melanoma Drug Stops Working

Research led by investigators at Memorial Sloan Kettering has identified a previously unknown mechanism of resistance to the newly approved melanoma drug, vemurafenib.

November 23, 2011
City of Hope and Memorial Sloan Kettering Receive NCI Grant to Train Nurses Caring for Cancer Survivors

A five-year grant of more than $1.4 million will fund a program to train nurses in helping survivors achieve the best possible quality of life after cancer.

October 17, 2011
Three Young Investigators Named Winners of Paul Marks Prize for Cancer Research

Memorial Sloan Kettering Cancer Center will recognize three young investigators for their exceptional bodies of innovative work that has helped to advance the field of cancer research. The researchers will receive the Paul Marks Prize for Cancer Research, an award presented biennially by Memorial Sloan Kettering to honor promising scientists under the age of 46.

September 20, 2011
Gene Mutation Contributes To Leukemia By Enhancing Function Of Blood Stem Cells

Memorial Sloan Kettering researchers helped to identify a key insight into what first goes wrong in the development of many leukemias.

June 30, 2011
First Comprehensive Analysis Of Gene Mutations In Ovarian Cancer Brings Patients One Step Closer To Personalized Medicine

According to a large-scale genomic analysis of the most common and aggressive type of ovarian cancer, researchers from Memorial Sloan- Kettering Cancer Center and other centers within The Cancer Genome Atlas (TCGA) project identified genetic mutations and pathways that distinctly set the disease apart not only from other types of ovarian cancer, but from other solid tumors as well.

June 29, 2011
Breast Cancer Treatment Shows Benefit For Women With Small, Localized Disease

Memorial Sloan Kettering Cancer Center physician-scientists report that women with small, node-negative, HER2-positive breast cancer may obtain a significant benefit from adjuvant chemotherapy with trastuzumab (Herceptin®), a drug previously shown to improve outcomes in advanced cancer and prevent the return of cancer in women diagnosed with higher-risk, early-stage, HER2-positive breast cancer. This study appears online in the journal Cancer, and will be published in a future print edition.

June 24, 2011
Groundbreaking Advances In The Treatment Of Advanced Melanoma Led By Physician-Researchers At Memorial Sloan Kettering Cancer Center

In an extraordinary demonstration of excellence, positive results from two separate studies of new therapies for the treatment of advanced melanoma were presented at the plenary session of the 2011 annual meeting of the American Society of Clinical Oncology by Paul Chapman, MD, and Jedd Wolchok MD, PhD, members of Memorial Sloan Kettering Cancer Center’s Melanoma and Sarcoma service, and lead authors on the studies along with collaborators from more than a one hundred cancer centers worldwide.

June 5, 2011
Syndicate content